News | Radiation Therapy | October 18, 2016

Yale research suggests patients treated at higher-volume facilities were more likely to have improved survival, shorter radiotherapy duration

intensity modulated radiation therapy outcomes, IMRT, head and neck cancers, facility volume, ASTRO 2016

October 18, 2016 — The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival. The findings were presented Sept. 26 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.

This study used the National Cancer Data Base to analyze 9,817 patients and found that patients treated at higher-volume facilities were more likely to have shorter radiation therapy duration than those at lower volume facilities.

The research team’s findings also revealed there was a 5.7 percent decreased hazard of death per additional 20 patients treated per year per facility. When annual facility case volume was defined based on a threshold of 95 cases/year (90th percentile), there was a 17.5 percent decreased hazard of death for higher-volume versus lower-volume facilities.

“Our findings suggest a strong relationship between higher-volume radiation therapy facilities and improved overall survival for patients treated with IMRT for locally advanced head and neck cancers,” said Henry S. Park, MD, MPH, first author on the study and a chief resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Further investigation should focus on the role of other factors potentially underlying this association, including radiation contouring, education, multidisciplinary communication, and toxicity management.”

For more information: www.astro.org


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now